• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    HCW Biologics Inc. filed SEC Form 8-K: Other Events

    4/22/25 5:15:08 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCWB alert in real time by email
    8-K
    0001828673false00018286732025-04-172025-04-17

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 17, 2025

     

     

    HCW Biologics Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40591

    82-5024477

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2929 N. Commerce Parkway

     

    Miramar, Florida

     

    33025

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 954 842-2024

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    HCWB

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

     


    Item 8.01 Other Events.

    As previously reported, HCW Biologics Inc. (the “Company”) entered into the “2022 Loan Agreement” with Cogent Bank on August 15, 2022, pursuant to which it received $6.5 million in proceeds to purchase a building that was planned to become the Company’s new headquarters and GMP manufacturing facilities (the “Property”). The loan is secured by a first priority lien on the building. On January 7, 2023, the Company entered into a Standard Form Agreement Between Owner and Design-Builder (the “Project Contract”), pursuant to which BE&K Building Group, LLC (“BE&K”) agreed to design, construct and improve the Property.

    On April 21, 2023, the Company entered into a credit agreement (the “Credit Agreement”) with Prime Capital Ventures, LLC (“Prime”) to obtain financing for the purpose of construction and renovation of the Property. As previously disclosed by the Company on Form 8-K filed on January 12, 2024, on January 10, 2024, after repeated and extended delays of the closing under the Credit Agreement, the Company exercised its right to terminate the Credit Agreement pursuant to its terms. The termination followed repeated delays in funding and related concerns. On September 27, 2024, the Company filed a claim in the bankruptcy proceedings of Prime in an attempt to get the Company’s ICA deposit returned. There can be no assurance that the Company will be successful in its efforts.

    During 2024, certain subcontractors filed mechanic’s liens related to unpaid invoices issued in connection with the Company’s construction and renovation of the Property. On December 16, 2024, BE&K the prime contractor on the project, sent the Company a draft, unfiled lawsuit and requested the parties discuss payment. On January 22, 2025, the Company entered into a forbearance agreement with BE&K to allow the Company until March 31, 2025 to continue efforts to obtain the financing required to complete the construction and renovation of the building. Pursuant to the forbearance agreement, the Company made a payment of $1.0 million in partial satisfaction of amounts owing to BE&K and its subcontractors. The 2022 Loan Agreement contains a provision for a discretionary default in the event that the Company fails to pay sums due in connection with construction of any improvements. Thus, beginning in the third quarter of 2024, the Company has reflected the Cogent Bank loan as short-term debt, net, to reflect that the lender has the right to accelerate the loan under a discretionary default provision at any time.

    On April 17, 2025, the Company received a summons and a copy of a complaint filed by BE&K in the Circuit Court of the 17th Judicial Circuit in and for Broward County, Florida (the “BE&K Complaint”). The BE&K Complaint was filed by BE&K Building Group, LLC as Plaintiff and each of the Company, Cogent Bank, B&I Contractors, Southern Painting, Dash Door & Closer Service, Inc., Fisk Electric Company and Lotspeich Co. of Florida as Defendants. BE&K Building Group, LLC v. HCW Biologics, et al., CACE-25-004668 (Fla. 17th Cir. Ct. 2025) (the “BE&K Litigation”). The Company, as a Defendant, is required to respond to the BE&K Complaint by May 7, 2025. In the Complaint, BE&K, claims, among other allegations, that the Company breached the Project Contract and the Forbearance Agreement and seeks a judgment to be entered against the Company for damages, interest, costs, and any other relief the court deems reasonable. Certain of the other defendants identified in the Complaint have filed responsive pleadings, including cross-claims against the Company, in the BE&K Litigation. In addition, the Company is informed that, on or about April 18, 2025, Fisk Electric Company (which is a defendant in the BE&K Litigation) filed a separate complaint in the Circuit Court of the 17th Judicial Circuit in and for Broward County, Florida (the “Fisk Complaint”) against the Company, BE&K, and the other defendants in the BE&K Litigation. Fisk Electric Company v. HCW Biologics, Inc, et al., CACE-25-005747 (Fla. 17th Cir. Ct. 2025) (the “Fisk Litigation”). The Company has not been served in the Fisk Litigation. The Company intends to respond in a timely fashion to the BE&K Complaint and cross-claims. The Company is currently seeking an alternative source of financing to satisfy the balances claimed under the mechanic’s liens filed by BE&K and subcontractors, as well as to complete the construction and renovation of the Property.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    HCW BIOLOGICS INC.

     

     

     

     

    Date:

    April 22, 2025

    By:

     /s/ Hing C. Wong

     

     

     

    Founder and Chief Executive Officer

     


    Get the next $HCWB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HCWB

    DatePrice TargetRatingAnalyst
    11/19/2021$10.00Buy
    EF Hutton
    More analyst ratings

    $HCWB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Wong Hing C bought $60,002 worth of shares (8,054 units at $7.45), increasing direct ownership by 2% to 501,911 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/20/25 4:35:35 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Winer Gary M bought $9,998 worth of shares (1,342 units at $7.45), increasing direct ownership by 49% to 4,075 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/20/25 4:35:07 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Garrett Scott T bought $100,001 worth of shares (13,423 units at $7.45), increasing direct ownership by 111% to 25,505 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/20/25 4:34:34 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Wong Hing C bought $60,002 worth of shares (8,054 units at $7.45), increasing direct ownership by 2% to 501,911 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/20/25 4:35:35 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Winer Gary M bought $9,998 worth of shares (1,342 units at $7.45), increasing direct ownership by 49% to 4,075 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/20/25 4:35:07 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Garrett Scott T bought $100,001 worth of shares (13,423 units at $7.45), increasing direct ownership by 111% to 25,505 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/20/25 4:34:34 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    EF Hutton initiated coverage on HCW Biologics with a new price target

    EF Hutton initiated coverage of HCW Biologics with a rating of Buy and set a new price target of $10.00

    11/19/21 8:39:08 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

    MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link between chronic inflammation and disease, today announced the pricing of its follow-on offering of an aggregate of 2,477,292 units at a purchase price of $0.6055 per unit priced at-the-market under Nasdaq rules. Each unit consists of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant, each to purchase one share of common stock. The warrant will have an exercise price of $0.6055 per share, will be exer

    2/17/26 9:50:56 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune

    HCW Biologics receiving cash fee and co-founder shares in Trimmunevalued at $7.0 million Trimmune will hold exclusive worldwide license for rights to high potential preclinical molecule created with HCW Biologics' TRBC drug development platform Initiation of Phase 1 clinical study expected in the first half of 2027 HCW Biologics retains royalty-free option to reclaim the rights to the Americas territory MIRAMAR, Fla., Feb. 13, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link between chronic inflamm

    2/13/26 8:30:00 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    SEC Filings

    View All

    HCW Biologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - HCW Biologics Inc. (0001828673) (Filer)

    2/19/26 4:43:57 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B4 filed by HCW Biologics Inc.

    424B4 - HCW Biologics Inc. (0001828673) (Filer)

    2/19/26 3:46:38 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by HCW Biologics Inc.

    EFFECT - HCW Biologics Inc. (0001828673) (Filer)

    2/18/26 12:15:07 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Leadership Updates

    Live Leadership Updates

    View All

    HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

    MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.  Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "These are exciting times at HCW Biologics. We achieved two major clinical milestones, with the completion of the Phase 1 clinical study to evaluate HCW9218 in solid tumors and the Phase 1b stu

    4/1/24 4:10:32 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Financials

    Live finance-specific insights

    View All

    HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

    MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2025.  On May 15, 2025, the Company closed an equity offering with gross proceeds of $5.0 million with a single institutional investor. Dr. Hing Wong, Founder and CEO, stated, "We are pleased to have completed a successful $5.0 million equity offering in a challenging market with

    8/18/25 2:44:03 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

    MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2022. "We have achieved several milestones in the first half of 2022, and some important pieces of our strategic plan have fallen into place. First, we are now a clinical-stage company, with the entry of our lead product candidate, HCW9218, into the clinic in a

    8/12/22 7:00:00 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

    MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022. "We continue to successfully execute our clinical development strategy which is based on our unique approach toward inflammaging," stated Hing C. Wong, Founder and CEO of HCW Biologics Inc. "HCW Biologics is developing immunotherapeutics that do not treat a single indica

    5/13/22 7:15:00 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by HCW Biologics Inc.

    SC 13D/A - HCW Biologics Inc. (0001828673) (Subject)

    11/22/24 4:53:35 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care